VYEPTI

Lundbeck faces FDA scrutiny over Vyepti's efficacy claims on its healthcare provider webpage. This regulatory action underscores the critical need for robust compliance in promotional materials. Procurement, regulatory affairs, and business development teams must reassess internal review processes to mitigate commercial risks associated with unsubstantiated marketing, impacting Vyepti's market position and Lundbeck's overall risk profile.

Lundbeck Seattle BioPharmaceuticals, Inc. secured the initial BLA approval for VYEPTI (EPTINEZUMAB-JJMR), a Type 1 New Molecular Entity, on February 21, 2020, under BLA761119. This intravenous Calcitonin Gene-related Peptide Antagonist has since received multiple supplemental FDA approvals for labeling and efficacy through June 5, 2026. This ongoing regulatory activity underscores Lundbeck's strategic commitment to expanding VYEPTI's market presence and therapeutic utility for stakeholders in procurement, regulatory affairs, and business development.